Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 2.09B.
Undervalued
The company’s latest PE is 22.15, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 161.40M shares, decreasing 15.71% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 93.00K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.83.